Explore more
News
Sanofi to Buy Vicebio for Up to $1.6 Billion
Digest more
Sanofi tightens grip on RSV, paying $1.15B upfront for Vicebio and boosting its pipeline beyond mRNA
Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...
Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has ...
A soon-to-be-released documentary film aims to change the conversation around hemophilia, a condition in which many female ...
Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...
GlobalData on MSN3d
Sanofi concludes Blueprint Medicines acquisition
Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...
Pharmaceutical Technology on MSN15h
Kling Bio and Sanofi link for antibodies and epitopes discovery
Using patient-derived B cells, Kling-Select facilitates the rapid detection of new antibodies and preserved viral epitopes.
A campaign backed by Kyowa Kirin, Amgen and Sanofi is calling on prominent organizations with medical websites to bring their ...
We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback